{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:09:21Z","timestamp":1786946961761,"version":"build-2736575974"},"reference-count":52,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To conduct a pilot study to examine topiramate for the treatment of weight gain associated with olanzapine in manic adolescents with bipolar disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a 12-week double-blind randomized placebo-controlled pilot study of topiramate (300\u2013400\u2009mg\/day) versus placebo in manic youth (ages 10\u201318 years) with bipolar disorder who were treated with olanzapine (10\u201320\u2009mg\/day). The primary outcome measure was gender- and weight-normed change in body mass index (BMI z-score).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Thirty manic adolescents were treated with olanzapine and were randomized to either topiramate (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200916) or placebo (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200914). There was a significantly greater increase in BMI z-scores in the placebo group (0.28 standard deviations [SDs]) compared with the topiramate group (0.10 SDs) when analyzed by longitudinal regression (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.049). The placebo group had greater increases in raw BMI and weight (2.25\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and 6.9\u2009kg, respectively) compared with the topiramate (0.99\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and 2.9\u2009kg) group (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.011 for BMI,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.016 for weight). The most common adverse events in the topiramate group were headache (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20097, 44%), gastrointestinal upset (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20093, 19%), and muscle stiffness (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20093, 19%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Topiramate may minimize the weight gain associated with olanzapine treatment in adolescents with bipolar disorder. Moreover, topiramate in combination with olanzapine was well tolerated. Larger studies that are adequately powered are necessary to determine the efficacy of topiramate for second-generation antipsychotic-related weight gain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration:<\/jats:title>\n                    <jats:p>\n                      <jats:uri xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:uri>\n                      Identifier number NCT00394095.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2022.0098","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T15:51:46Z","timestamp":1683042706000},"page":"126-133","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["A Double-Blind Placebo-Controlled Pilot Study of Topiramate in Manic Adolescents Treated with Olanzapine"],"prefix":"10.1177","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1837-4126","authenticated-orcid":false,"given":"Melissa P.","family":"DelBello","sequence":"first","affiliation":[{"name":"Division of Bipolar Disorders Research, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn M.","family":"Bruns","sequence":"additional","affiliation":[{"name":"Division of Bipolar Disorders Research, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bloom","sequence":"additional","affiliation":[{"name":"Division of Bipolar Disorders Research, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1574-151X","authenticated-orcid":false,"given":"Luis Rodrigo","family":"Patino Duran","sequence":"additional","affiliation":[{"name":"Division of Bipolar Disorders Research, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7526-2641","authenticated-orcid":false,"given":"Jeffrey","family":"Strawn","sequence":"additional","affiliation":[{"name":"Division of Bipolar Disorders Research, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb M.","family":"Adler","sequence":"additional","affiliation":[{"name":"Division of Bipolar Disorders Research, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Welge","sequence":"additional","affiliation":[{"name":"Division of Bipolar Disorders Research, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"AIMS: ECDEU Assessment Manual for Psychopharmacology (revised edition). Rockville (Maryland) U.S. Department of Health Education and Welfare 1976 pp. 534\u2013535."},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.4103\/jrms.jrms_672_21"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"e_1_3_3_5_1","first-page":"53","article-title":"disorders","volume":"14","author":"Barzman DH","year":"2004","unstructured":"Barzman DH, , DelBello MP, , Kowatch RA, , Warner J, , Rofey D, , Stanford K, , Rappaport K, , Daniels JP, , Strakowski SM: Adjunctive topiramate in hospitalized children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol, 14:53\u2013600, 2004.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"e_1_3_3_6_1","unstructured":"Cohen J: The analysis of variance. In: Statistical Power Analysis for the Behavioral Sciences (2nd ed.). New Jersey Lawrence Earlbaum Associates 1988 pp. 273\u2013406."},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e318040b25f"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000220851.94392.30"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1549"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2010.00798.x"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2010.09.011"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300950"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000159151.75345.20"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000194567.63289.97"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/104454602762599862"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/10398562.2010.539609"},{"key":"e_1_3_3_17_1","first-page":"25","article-title":"stabilizers","volume":"8","author":"Fiedorowicz JG","year":"2012","unstructured":"Fiedorowicz JG, , Miller DD, , Bishop JR, , Calarge CA, , Ellingrod VL, , Haynes WG: Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers. Curr Psychiatry Rev, 8:25\u201336, 2012.","journal-title":"Curr Psychiatry Rev"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-006-0602-7"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-008-0105-9"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0009922814542481"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0717"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/10445460152595568"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199203000-00011"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200104000-00014"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1076\/chin.6.3.235.3152"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13370-3"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100034855"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10578-022-01424-6"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2004.03.008"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.10.001"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2005.02.001"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000172994.56028.c3"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2006.00276.x"},{"key":"e_1_3_3_34_1","first-page":"150","article-title":"meta-analysis","volume":"35","author":"Maayan L","year":"2010","unstructured":"Maayan L, , Vakhrusheva J, , Correll CU: Effectiveness of medications used to attenuate antipsychotic-related weight gain in metabolic abnormalities: A systematic review and meta-analysis. Neuropsychopharmacology, 35:150\u20131530, 2010.","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31827cb2b7"},{"key":"e_1_3_3_36_1","first-page":"1","article-title":"profiles","volume":"7","author":"Mahmoudi-Gharaei J","year":"2012","unstructured":"Mahmoudi-Gharaei J, , Shahrivar Z, , Faghihi T, , Mohammadi MR, , Tehrani-Doost M, , Alaghband-Rad J, , Ghaeli P: Topiramate versus valproate sodium as adjunctive therapies to a combination of lithium and risperidone for adolescents with bipolar I disorder: Effects on weight and serum lipid profiles. Iran J Psychiatry, 7:1\u201310, 2012.","journal-title":"Iran J Psychiatry"},{"key":"e_1_3_3_37_1","first-page":"457","article-title":"review","volume":"22","author":"Martinez-Ortega JM","year":"2013","unstructured":"Martinez-Ortega JM, , Funes-Godoy S, , Diaz-Atienza F, , Gutierrez-Rojas L, , Perez-Costillas L, , Gurpegui M: Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: A critical review. Eur Child Adolesc Psychiatry, 22:457\u2013479, 2013.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.08.008"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2010.00797.x"},{"key":"e_1_3_3_40_1","first-page":"839","article-title":"Scale","volume":"21","author":"National Institute of Mental Health: CGI (Clinical Global Impressions)","year":"1985","unstructured":"National Institute of Mental Health: CGI (Clinical Global Impressions). Scale. Psychopharmacol Bull, 21:839\u2013843, 1985.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000162806.46453.38"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.64.4.442"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.07.005"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091217415621266"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2012-1246"},{"key":"e_1_3_3_47_1","first-page":"166","article-title":"olanzapine","volume":"18","author":"Strawn JR","year":"2008","unstructured":"Strawn JR, , Adler CM, , Strakowski SM, , DelBello MP: Hyperthermia and rhabdomyolysis in an adolescent treated with topiramate and olanzapine. J Child Adolesc Psychopharmacol, 18:166\u2013188, 2008.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"e_1_3_3_48_1","first-page":"176","article-title":"Olanzapine in the treatment of acute mania in adolescents with bipolar I disorder: A 3-week randomized double-blind placebo-controlled study","volume":"1","author":"Tohen M","year":"2005","unstructured":"Tohen M, , Kryzhanovskaya L, , Carlson G, , DelBello MP, , Wozniak J, , Kowatch R, , Wagner K, , Findling R, , Lin D, , Robertson-Plouch C, , Xu W, , Huang X, , Dittman R, , Biederman J: Olanzapine in the treatment of acute mania in adolescents with bipolar I disorder: A 3-week randomized double-blind placebo-controlled study. Neuropsychopharmacology 30(Suppl. 1):176, 2005.","journal-title":"Neuropsychopharmacology 30(Suppl"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.0024"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-020-00319-x"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2009.0042"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(02)00251-8"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2022.0098","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2022.0098","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2022.0098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:56:38Z","timestamp":1777388198000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2022.0098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1089\/cap.2022.0098"],"URL":"https:\/\/doi.org\/10.1089\/cap.2022.0098","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}